INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Soteropoulos Paula reported DNTH

Director · Dianthus Therapeutics, Inc. /DE/ · Dianthus Therapeutics, Inc. /DE/ — Stock Option (Right to Buy)

Side
M
Value
—
Shares
27.6K
Price
—
Executed
Mar 24, 2026
Disclosed
Mar 26, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 24 executedMar 26, 2026 disclosed

DNTH · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DNTH

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M—
    9,375 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    12
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Open-market sale · 10b5-1 plan
    		SELL$767K
    7,215 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    8
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Open-market sale · 10b5-1 plan
    		SELL$273K
    2,600 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    7
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M$136K
    6,249 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    7
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M$207K
    9,375 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M—
    6,249 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    19
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Open-market sale · 10b5-1 plan
    		SELL$1.42M
    13.3K sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    7
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M$134K
    7,500 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    0
    RS
    Randhawa SimratEVP, Head of R&D
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M—
    7,500 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    11
    VM
    Veness Adam MSVP, General Counsel and Sec.
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise
    		M$273K
    15.0K sh
    		Aug 13, 2026Aug 14, 2026
    traded Aug 13, 2026
    		+1dSEC FORM 4

    Evidence

    13
    VM
    Veness Adam MSVP, General Counsel and Sec.
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise
    		M—
    15.0K sh
    		Aug 13, 2026Aug 14, 2026
    traded Aug 13, 2026
    		+1dSEC FORM 4

    Evidence

    25
    MA
    McGeorge AnneDirector
    DNTHDianthus Therapeutics, Inc. /DE/
    Open-market sale · 10b5-1 plan
    		SELL$78K
    700 sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    25
    MA
    McGeorge AnneDirector
    DNTHDianthus Therapeutics, Inc. /DE/
    Open-market sale · 10b5-1 plan
    		SELL$111K
    1,000 sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    3
    VM
    Veness Adam MSVP, General Counsel and Sec.
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M—
    3,833 sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    1
    VM
    Veness Adam MSVP, General Counsel and Sec.
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M$289K
    16.2K sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    28
    VM
    Veness Adam MSVP, General Counsel and Sec.
    DNTHDianthus Therapeutics, Inc. /DE/
    Open-market sale · 10b5-1 plan
    		SELL$356K
    3,217 sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    3
    VM
    Veness Adam MSVP, General Counsel and Sec.
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M—
    16.2K sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    17
    MA
    McGeorge AnneDirector
    DNTHDianthus Therapeutics, Inc. /DE/
    Open-market sale · 10b5-1 plan
    		SELL$156K
    1,450 sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    2
    VM
    Veness Adam MSVP, General Counsel and Sec.
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M$69K
    3,833 sh
    		Aug 7, 2026Aug 11, 2026
    traded Aug 7, 2026
    		+4dSEC FORM 4

    Evidence

    14
    MA
    McGeorge AnneDirector
    DNTHDianthus Therapeutics, Inc. /DE/
    Option exercise · 10b5-1 plan
    		M$73K
    6,500 sh
    		Aug 10, 2026Aug 11, 2026
    traded Aug 10, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001692444-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 24, 2026
    Published
    Mar 26, 2026
    Ingested by INSIDER
    Nov 5, 04:09 UTC
    Last re-read
    Nov 5, 04:09 UTC

    Extracted facts

    Filer
    Soteropoulos Paula
    Role
    Director
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Dianthus Therapeutics, Inc. /DE/ — Stock Option (Right to Buy)
    Ticker
    DNTH
    Shares
    27.6K
    Price per share
    $0
    Execution date (reported)
    Mar 24, 2026
    Owned after transaction
    1,198 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    What this establishes

    Soteropoulos Paula filed this Form 4 reporting a option exercise of DNTH on Mar 24, 2026. It became public on Mar 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Soteropoulos Paulacik:0001692444
    Issuer
    Dianthus Therapeutics, Inc. /DE/cik:0001690585

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.